Although EGFR and KRAS mutations typically occur in a mutually exclusive fashion in lung cancer (39, 40); anecdotal reports show evidence of co-occurrence of KRAS and EGFR mutations in lung cancer patients (41–43). Here, EGFR is linked to lung carcinoma.